Literature DB >> 7705762

Glucose clamps with the Biostator: a critical reappraisal.

L Heinemann1, F J Ampudia-Blasco.   

Abstract

The Biostator makes it possible to perform glucose clamp experiments almost automatically. Thus, blood glucose concentrations can be maintained at (or close to) a target level with substantially less effort than with the manual clamp technique. The automatisation also avoids a potential bias on the part of the investigator. However, as with the non-automated manual clamp technique, blood glucose concentrations do not remain exactly at the target value, as they show a considerable scatter around the target value. This scatter is generated by the time constants of the Biostator, i.e. the whole closed-loop system, and the autoregressive properties of the glucose clamp algorithm used. In order to describe the quality of glucose clamps over time more precisely, "cumulative sums" as an alternative to the usual coefficient of variation can be used. Practical work with the Biostator is burdened with technical difficulties and considerable costs in comparison to the manual clamp technique. Deficits concerning data storage and presentation capability of the Biostator have been overcome by an appropriate programme for an external computer. The use of the Biostator for the glucose clamp technique is not mandatory, but, the use of this machine makes it possible to perform glucose clamp studies under standardised and reproducible conditions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7705762     DOI: 10.1055/s-2007-1001763

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  12 in total

Review 1.  Can technological solutions for diabetes replace islet cell function?

Authors:  Justin M Gregory; Daniel J Moore
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

2.  In silico evaluation of an artificial pancreas combining exogenous ultrafast-acting technosphere insulin with zone model predictive control.

Authors:  Justin J Lee; Eyal Dassau; Howard Zisser; Rebecca A Harvey; Lois Jovanovič; Francis J Doyle
Journal:  J Diabetes Sci Technol       Date:  2013-01-01

3.  How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device.

Authors:  Carsten Benesch; Tim Heise; Oliver Klein; Lutz Heinemann; Sabine Arnolds
Journal:  J Diabetes Sci Technol       Date:  2015-04-07

4.  Control oriented model of insulin and glucose dynamics in type 1 diabetics.

Authors:  Pier Giorgio Fabietti; Valentina Canonico; Marco Orsini Federici; Massimo Massi Benedetti; Eugenio Sarti
Journal:  Med Biol Eng Comput       Date:  2006-03       Impact factor: 2.602

Review 5.  Clinical pharmacokinetics and pharmacodynamics of insulin aspart.

Authors:  A Lindholm; L V Jacobsen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Dose-response effects of insulin glargine in type 2 diabetes.

Authors:  Zhihui Wang; Maka S Hedrington; Nino Gogitidze Joy; Vanessa J Briscoe; M Antoinette Richardson; Lisa Younk; Wendell Nicholson; Donna B Tate; Stephen N Davis
Journal:  Diabetes Care       Date:  2010-03-31       Impact factor: 17.152

7.  The artificial pancreas: how sweet engineering will solve bitter problems.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2007-01

8.  Precision and accuracy of hyperglycemic clamps in a multicenter study.

Authors:  Kieren J Mather; Ashley H Tjaden; Adam Hoehn; Kristen J Nadeau; Thomas A Buchanan; Steven E Kahn; Silva A Arslanian; Sonia Caprio; Karen M Atkinson; Melanie Cree-Green; Kristina M Utzschneider; Sharon L Edelstein
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-03-01       Impact factor: 4.310

9.  New Clamp-PID Algorithm for Automated Glucose Clamps Improves Clamp Quality.

Authors:  Carsten Benesch; Mareike Kuhlenkötter; Leszek Nosek; Tim Heise
Journal:  J Diabetes Sci Technol       Date:  2021-02-10

10.  Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.

Authors:  Ralph A DeFronzo; Marcus Hompesch; Sreeneeranj Kasichayanula; Xiaoni Liu; Ying Hong; Marc Pfister; Linda A Morrow; Bruce R Leslie; David W Boulton; Agatha Ching; Frank P LaCreta; Steven C Griffen
Journal:  Diabetes Care       Date:  2013-06-04       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.